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Introduction
Detection of HLA-G by Gerathy et al. [9] in 1987 has
begun  further study on role of its expression, and
function of non-classical Ib class antigens. Thorough
investigation of HLA-G antigen expression in preg-
nancy at maternal-placental interface [5,19,22] and its
influence on maintenance of  maternal immune toler-
ance of the for semiallogenic embryo was initiated [1].
HLA class I and II antigens ( HLA-A, -B, -C, -DR, -
DQ and -DP), which not only play the key role in
transplantology but are also associated with various
autoimmune disorders, were described in detail [4,32]. 
Non-classical HLA class I antigens (HLA-E, -F and
-G), particularly HLA-G became the target of research
regarding autoimmune response by inhibition of cyto-
toxic T cells (CTL) and NK cells function [21]. It is
known, that HLA-G antigen gene is localized at the
short arm of chromosome 6, coding for two forms of
protein: cell membrane-liked and soluble [20,28]. It
has been also proven, that soluble protein sHLA-G is
present in maternal serum during pregnancy [19], in
the placental blood and amniotic fluid [7,28]. Clinical
research have indicated that certain immunologic situ-
ations significantly influence plasma sHLA concentra-
tion [24]. 
During pregnancy the following changes in sHLA-I
plasma concentration were observed: significant rise
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in first and second trimester, with subsequent marked
decrease in the third and during labor. sHLA-I levels
during delivery were lower in comparison to the
maternal blood [16]. Rebmann et al. [27] noted that
both in placental blood and amniotic fluid sHLA con-
centrations were lower than in maternal blood. Our
own study carried out in the group of women with
high-risk pregnancy (APS, IUGR, PE) increased levels
of sHLA-I were positively correlated with IFN gamma
levels [30]. 
It was observed that variance in expression of
sHLA-G proteins is associated with HLA-G alleles
with sHLA-G levels being genetically controlled thus
influencing function of immune regulation on various
levels by sole existence of alleles responsible for
"high" and "low" soluble form secretion [28]. 
Pfeifer et al. [24] have observed increased risk of
idiopathic recurrent spontaneous abortions after IVF
among women with low concentration of sHLA-G in
peripheral blood in comparison to women with high
levels this soluble antigen.
The aim of work is assessment of association
between of soluble HLA-G and HLA-I concentration
with HLA-G alleles and genotypes among women
with spontaneous abortions in the first trimester of
pregnancy in comparison to fertile women.  
Materials and methods
Patients. Eighty women enrolled into the study were divided into
two groups. The study group (S) comprising of sixty individuals
with pregnancy failures included twenty women with three sponta-
neous abortions in the first trimester of pregnancy (RSA), twenty
women with blighted ovum - "empty sac" (ES) and twenty women
with triple IVFf failures. The control group (C ) comprised of
twenty fertile women, who gave birth to at least two children in the
past. In the group with pregnancy failures the following concurrent
factors were excluded: karyotype abnormalities, hormonal distur-
bances, anatomical uterine malformations, infectious agents and
autoimmune disorders [anti-cardiolipin antibodies (ACLA) and
antinuclear antibodies (ANA) were tested]. 
sHLA I concentration in peripheral blood. sHLA class I were
detected by ELISA method. Maxisorb plates (NUNC, Wiesbaden,
Germany) coated overnight in 4°C with 100 μl with rabbit anti-
mouse IgG antibody (DAKO, Zurich, Switzerland) (1:500 dilu-
tion) were subsequently washed tree times with 300 μl of
TWEEN20/PBS 0,02% solution (PBST) and incubated for one
hour in the room temperature with 100 μl a-HLA I W6/32 serum
(DAKO, Zurich, Switzerland) (1:500 dilution). Another washing
with PBST was performed, the blocking with 300 μl of 3% BSA
(Amersham, Pittsburgh, USA) for one hour in the room tempera-
ture was performed.
The plates were washed with PBST, and 100 μl of standard
serum (courtesy of **) or of analyzed serum concentration was
added and incubated in the room temperature for one hour. In the
next step washing with 300  l of PBST (5x) was performed with
subsequent incubation with 100 μl of peroxydase conjugated
anti- 2microglobulin (DAKO, Zurich, Switzerland). Following
the incubation intensive washing was done (10×300 μl of PBST).
The reaction was blocked after 15 minutes with 0,5 M H2SO4.
Absorbance was measured at  =490 nm  ref=630 nm with BIO-
TEK microplate reader (BIO-TEK Instruments Inc, Vermont,
USA). 
sHLA-G concentration in peripheral blood. The analysis was
performed with ELISA method with kits purchased from Bio Ven-
dor Laboratory Medicine,Inc (catalogue no. RD194070100). Ana-
lytical sensitivity - 2 Units/ml. 
Standard and analysed serums were added to the microplate
wells, previously coated with mouse monoclonal a-sHLA-G anti-
body. Following one-hour incubation in the room temperature
sHLA-G in the serum links with monoclonal antibody. Free anti-
body is washed-out in automatic washer with washing buffer. To
all wells the conjugate is added (mouse monoclonal antibody
(enzyme conjugated a-human β2-mikroglobulin). Subsequent
incubation for one hour in the room temperature is performed.
Excess of the conjugate is washed out with the washing buffer.
Having added the enzyme substrate color reaction is performed
with intensity relative to the sHLA-G concentration in the analysed
samples. The reaction is stopped after 10 minutes of incubation
with absorbance being measured with the reader at wavelength
λ=450 nm. Sandard curve is used to establish the concentration of
proteins in the analyzed samples. 
HLA-G typing. In all patients direct sequencing of exons 2,3 and
4 of HLA-G gene was performed. Genomic DNA was isolated
from the peripheral blood leukocytes by purification with phe-
nol/chloroform and precipitation with ethanol. DNA amplification
was performed using polymerase chain reaction with primers and
conditions as described previously [23]. After purification in
Microcon-100 columns (Amicon) PCR products were sequenced
with the same primers, using fluorescently labelled dideoxy chain
terminators from an ABI Prism v 3.0 kit (Applied Biosystems) in
an ABI 377 automated sequencer. ABI PRISM 377 Collection
Software and Sequencing Analysis Software version 3.0 were used
for data collection and analysis.
Definition of HLA-G allele. HLA-G alleles were identified by
comparison of the sequences of exon 2, 3 and 4 in the patients with
the sequences of HLA-G alleles published at the Nolan Research
Institute website.
Statistical analysis. sHLA- I and sHLA-G concentrations were
described by ± standard error of the mean (SEM). To analyze sta-
tistical differences between continuous variables for different
groups the U Mann-Whitey test corrected for group size. Ko³-
mogorov-Smirnov test was used to establish sHLA-G  concentra-
tion ranges which would most appropriately differentiate between
the groups. 
Non-continuous variables were described by the number and
prevalence. To analyze statistical correlations between non-contin-
uous variables Pearson's Chi-square test, Fisher's exact test and
logistic regression model were used. P values of p<0,05 were con-
sidered significant in all performed tests. Borderline significance
was defied as p>0,05 and p<0,10. STATISTICA-6,0 and STATA-
5,0 were used for statistical analyses. 
Ethical issues. Consent to the experiments was obtained from the
Ethical Board for Animal Experimentation PAM- BN- 001/131/02
Results
As shown in the Table 1 the highest concentration of
sHLA-I is noted among women with HLA-G 10401
allele (513,4 89,5 SEM ng/ml) which differed signifi-
cantly for the mean sHLA-I concentration calculated
for all the remaining alleles (p<0.0001). The most
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prevalent alleles were: HLA-G 10101, 10102 and
10108 with sHLA-I concentrations among women
bearing those alleles significantly lower in comparison
to the HLA-G 10401 carriers (p<0.001). Allele 10101
and 10102 was related to the lower plasma sHLA-I
concentrations than 10108 allele (p<0.02). The highest
concentrations of sHLA-G was found among HLA-G
10102, 10101 and 10108 allele carriers, however with
no statistical differences noted between the alleles. 
Table 2 indicates that the highest mean values for
sHLA-I was noted in BO group (252.3 ± 43.8 SEM
U/ml); No differences noted in mean concentration of
sHLA-I between the groups. Lowest mean sHLA-G
values were observed in the IVFf  group (3.32 ± 0.90
SEM ng/ml) with significant difference from the
remaining groups (p<0.05).
Discussion
In spite of the extensive research regarding possible
role of both membrane-linked and soluble forms of
HLA-G at the maternal-placental interface no conclu-
sive relation with pregnancy outcome was elucidated
so far. Moreover, its role in the blastocyst implantation
and IVF success remains unclear. 
It is suspected that soluble forms of  HLA-G are
probably transported form the mononuclear peripheral
blood cells  containing HLA-G mRNA [13,10]. While
the most important source for sHLA-I proteins are
liver and lymphocytes [2]. Soluble HLA-G was most-
ly found in the syncytiotrophoblast and other tro-
phoblastic cells [15,17,19]. 
Expression of soluble HLA-G is related to the
Fas/FasL related  CD4+ and CD 8+  T-lymphocyte
apoptosis [3,6,11]. HLA-G1 ad soluble isoform HLA-
G5 protects from lysis by Tc lymphocytes. Of the sol-
uble HLA-G isoforms present in serum during preg-
nancy the main one is sHLA-G2, which does not bind
β2m.  Izoform sHLA-G1 includes α2 domain neces-
sary to bind β2m and peptides between light and heavy
chains while sHLA-G2 does not include  α2 domain
and binds itself into HLA homodimers similar to class
II, which do not recognize β2m but may bind peptides
[12]. 
sHLA-G presence in culture supernatants from IVF
is linked with high degree of success in the procedure
[15,29]. Other studies where failures to implant in the
situation of sHLA-G absence in the pre-implantation
supernatants from embryonic cultures support this the-
sis [8,23,32]. 
Rizzo et al. [30] suggest a role for sHLA-G mole-
cules in the ovulatory process and propose the  follic-
ular fluids(FFs) analysis for sHLA-G molecule pres-
ence as a useful tool oocyte selection in IVF.
In our study we found that the highest concentra-
tion of sHLA-I was noted among women with sHLA-
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Table 1. sHLA I and sHLA G concentrations (mean  SEM) correlated with alleles in the studied group. 
asHLA I concentrations lower in comparison to the ones noted for 10401 allele with p<0,001; bsHLA I concentrations lower in comparison to the ones
noted for 10108 allele with p<0,02; p*- statistical significance with the analyzed allele in comparison to the remaining alleles 
Table 2. Mean (± SEM) concentrations of sHLA I and sHLA-G in
each of the subgroups among women with pregnancy failures (BO,
RSA, IVFf,) and in the control group (C ) 
alowest sHLA-G concentrations in comparison to the IVFf group with
p<0,05 (U Mann-Whitney test)
G 10401 allele (513.4 ± 89.5 SEM ng/ml ) and differed
significantly form mean sHLA-I concentrations calcu-
lated for all the remaining alleles (p<0.0001). The
most prevalent HLA-G alleles were 10101, 10102 and
10108 related to significantly lower mean sHLA-I val-
ues in comparison to HLA-G allele 10401(p<0.001).
Among HLA-G allele 10101 and 10102 carriers sig-
nificantly lower levels of sHLA-I in analysed samples
were noted than among 10108 allele carriers (p<0.02).
We have observed that the highest sHLA-G mean con-
centrations were observed among HLA-G 10102,
10101 and 10108 carriers, with insignificant concen-
tration differences related to each of these alleles. 
In our research the highest values of mean sHLA-I
concentration was found in the BO group (252.3   43.8
SEM U/ml);  No significant difference in mean sHLA-
I concentrations between the groups was noted. The
lowest mean sHLA-G levels were observed in the IVFf
group  (3.32   0.90 SEM ng/ml) differing significantly
from the remaining groups (p<0.05). 
Differently from the results obtained in our study,
Rebmann et al. [28] have found that among people
bearing HLA-G 01013 allele (8.1 ± 1.7 SEM ng/ml) or
"null" allele HLA-G 0105N (8.2 ± 3.2 SEM ng/ml)
significantly lower serum levels of  sHLA-G in com-
parison to people bearing other alleles were noted,
while individuals with HLA-G 01041 allele tended to
present significantly higher sHLA-G levels (42.5 ± 4.6
SEM ng/ml), which may indicate genetic control over
sHLA-G secretion on various levels of immune regu-
lation by existence of HLA-G alleles responsible for
"high" and "low" secretion of soluble forms [28]. In
the previous studies Rebmann et al. [27] have proven
that mean sHLA-G concentrations did not differ
between men (24.9 ± 3.0 SEM ng/ml) and women
(20.1 ± 2.1SEM ng/ml), but among HLA-A11 carriers
sHLA-G concentrations (13.0 ± 2.0 SEM ng/ml) were
significantly (p<0.001) lower than among other HLA-
A allele carriers. These researchers have also observed
that sHLA-G levels during labor did not differ signifi-
cantly from the control group, while being significant-
ly (p<0.001)  lover in placental blood (13.8 ± 1.5 SEM
ng/ml). Mean sHLA-G values (15.5 ± 1.0 SEM ng/ml)
in amniotic fluid were significantly (p<0.001) lower
than in plasma, while individual sHLA-G levels did
not correlate with sHLA-I levels [27]. 
Hunt et al. [12] while assessing sHLA-G levels in
pregnancy have observed that these concentration
increase in the first trimester of pregnancy reaching
plateau in the second and third trimester, with moder-
ate decrease at the end of pregnancy. Other researcher
when studying sHLA-G concentrations among preg-
nant women and non-pregnant did not observe signifi-
cant differences [14,24,26]. 
Implantation of embryo in the procedure of IVF
remains a difficult process, as 62% of oocytes may be
rejected after 12th week of pregnancy with key role for
fetus survival is also played by sHLA-G2 [8]. 
Lately, many researchers have been investigating
the expression of this molecule, especially sHLA-G in
the supernatants from oocyte culture, and its influence
on embryo survival following the transfer [31,35]. 
Van Lierop et al. [34] during research into human
embryos culture in 8 cell morula before formation of
blastocyst did not detect sHLA-G. 
Noci et al. [23] have shown the presence of sHLA-
G in 36.2% of single embryo cultures after 72 hours,
while in 8.9% of cultures sHLA-G was detected after
48 hours. Sher et al. [32] while investigating 594
embryos form 201 women observed presence of
sHLA-G among at least one embryo from 65% of
women. 
Pfeiffer et al. [24] have found that women with IVF
failure manifested by spontaneous abortion in the early
pregnancy presented lower sHLA-G and sHLA-I lev-
els in the pre-ovulation period and during pregnancy
compared to women with normal pregnancy.
In pregnancy failures manifesting as blighted ovum
- "empty sac" (ES) concentrations of soluble HLA-I
and sHLA-G were not investigated so far nor was the
association between the concentration and HLA-G
polymorphisms. 
sHLA-G molecules is associated to certain HLA-G
alleles and imply that sHLA-G levels are under genet-
ic control. Low concentration sHLA-G seems to be
prognostically important in IVF failure. 
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